Galmed Pharmaceuticals Ltd. (EOCN)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $3.20
- As of
Kresmion compiles this page from EOCN's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Galmed Pharmaceuticals Ltd. (EOCN): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-09-09.
See the full EOCN dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for EOCN on one page. Preview it with sample data, then open it live with a free account.
Preview the EOCN dossierActive events for EOCN
No recent events on EOCN in the last 180 days.
FREE, NO ACCOUNT
Every event on EOCN, as it fires
New filings, 13F moves and cross asset events on EOCN land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in EOCN (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP M47238148 · 2026Q2 | $48K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, EOCN
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
EOCN against its peers
EOCN's return on equity of -65.3% ranks in the 77th percentile of 14 Biotechnology sub-industry peers, fiscal periods ending between 2025-03-31 and 2026-04-30.
| Metric | EOCN | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 72102 | n/a | 9 |
| Gross margin | n/a | 80.6% | n/a | 7 |
| Operating margin | n/a | -3769.1% | n/a | 8 |
| Net margin | n/a | -4141.7% | n/a | 8 |
| Return on equity | -65.3% | -212.6% | 77 | 14 |
Peers (20): BCAB, CMND, SILO, APVO, SXTP, ERNA, EMMA, LSBCF.D, MBIO, HCWB, CVKD, VIVS, DCOY, JUNS, CLDI, GRI, ABPO, KALA, ACUT, PMCB. Left out: VCNX (period gap), AGNPF (no annual filing), BIXT (no annual filing), GPLL (period gap), BVAXF (no annual filing). Fiscal periods ending between 2025-03-31 and 2026-04-30. Every figure is one full fiscal year read from one annual filing (EOCN: 20-F), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow EOCN on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to EOCN for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.